ArticleJournal of molecular histology2026
Berberine improves colon damage of ulcerative colitis colonic epithelium by activating TAS2R38 signaling pathway.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota-Immune-Barrier Axis.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUlcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease. Current treatment options have limitations in terms of efficacy and side effects. TAS2R38 is an important bitter taste receptor, and recent studies have suggested its potential role in gut immune regulation. This study aims to explore the role of the TAS2R38 receptor in UC and evaluate its potential as a therapeutic target.
methodsA 3% DSS solution was used to induce colitis in mice. The expression of TAS2R38 and its downstream signaling pathway was assessed using immunohistochemistry, Western blot, and immunofluorescence. Through molecular docking and pharmacological screening, bitter compounds, that bind to TAS2R38 were identified. The therapeutic effects of bitter compounds on DSS-induced colitis were evaluated by monitoring body weight, measuring colon length, conducting HE staining, and assessing the mucus layer integrity.
resultsIn the DSS-induced colitis mouse model, the TAS2R38 signaling pathway was found to be inhibited, particularly with a significant reduction in the expression of the downstream proteins PLCβ2 and IP3R3. Pharmacological screening and molecular dynamics simulations revealed that berberine strongly binds to TAS2R38 and effectively prevents DSS-induced colitis by activating this receptor. Berberine treatment significantly alleviated symptoms such as weight loss, diarrhea, and fecal occult blood, and improved colon length, spleen weight, and disease activity index (DAI). Additionally, HE staining showed that berberine significantly reduced DSS-induced epithelial damage and restored intestinal mucus barrier integrity.
conclusionThis study suggests that the TAS2R38 receptor may play a key role in the pathogenesis of ulcerative colitis. Berberine, by activating the TAS2R38 signaling pathway, exerts significant protective effects in DSS-induced colitis. TAS2R38 could be a potential therapeutic target for UC, and berberine, as a traditional Chinese medicine component, holds promise as a treatment for UC.
Indexed as
Identifiers
41758269What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.